Welcome to our dedicated page for Neurocrine Biosciences news (Ticker: NBIX), a resource for investors and traders seeking the latest updates and insights on Neurocrine Biosciences stock.
Neurocrine Biosciences Inc. (Nasdaq: NBIX) is a premier neuroscience-focused biopharmaceutical company based in San Diego. Established in 1992, the company is committed to developing and commercializing innovative pharmaceutical products that address unmet medical needs. Neurocrine Biosciences specializes in treatments for neurological, neuroendocrine, and neuropsychiatric disorders, impacting some of the largest pharmaceutical markets worldwide, including segments dealing with endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other related conditions.
The company’s extensive portfolio includes FDA-approved treatments such as INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease, along with investigational candidates like elagolix, opicapone, and crinecerfont. Notable late-stage clinical programs are:
- Elagolix: A hormone-releasing antagonist for women's health, particularly in treating endometriosis and uterine fibroids in collaboration with AbbVie.
- Opicapone: A catechol-O-methyltransferase (COMT) inhibitor for Parkinson's disease patients.
- Ingrezza: For treating Tourette syndrome and other movement disorders.
Recently, Neurocrine announced the initiation of a Phase 1 clinical study for NBI-1076986, an investigational M4 subtype-selective muscarinic acetylcholine receptor antagonist aimed at treating movement disorders such as Parkinson's disease tremor and dystonia. This is part of their broader muscarinic receptor-focused portfolio, which includes a variety of small molecule M1, M1/M4, and M4 agonists acquired from Nxera Pharma.
Neurocrine's robust pipeline also includes the CAHtalyst™ studies, which focus on crinecerfont for congenital adrenal hyperplasia (CAH), demonstrating significant potential in reducing glucocorticoid doses while maintaining androgen control. Their recent presentations at the American Association of Clinical Endocrinology 2024 Annual Meeting and the European Congress of Endocrinology 2024 highlight their continuous advancements.
Financially, Neurocrine Biosciences maintains a strong position with a multi-billion-dollar product in INGREZZA, and a diverse pipeline of 17 clinical development programs. Notably, the company announced the retirement of CEO Kevin Gorman, Ph.D., with Kyle Gano, Ph.D., set to succeed him in October 2024, ensuring a seamless transition and continued focus on innovative treatments.
For more comprehensive insights and updates, visit Neurocrine Biosciences and follow them on LinkedIn, X (formerly Twitter), and Facebook.
Neurocrine Biosciences (NASDAQ: NBIX) has announced a conference call and webcast scheduled for May 3, 2023, to discuss its Q1 2023 financial results. The press release will be available at
Neurocrine Biosciences (NASDAQ: NBIX) will present at the Stifel 2023 CNS Days on Tuesday, March 28, 2023, at 12:30 p.m. Eastern Time. Eiry Roberts, Chief Medical Officer, and Kyle Gano, Chief Business Development and Strategy Officer, will represent the company.
The live presentation will be webcasted and can be accessed on Neurocrine's website under the Investors section. A replay of the event will be available about one hour after the presentation and archived for one month.
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced the publication of data from the RE-KINECT study, the largest real-world analysis of patients with possible tardive dyskinesia (TD). The study showed that patients aware of their involuntary movements reported significant negative impacts on their health and social functioning. An important finding was the disconnect between clinician-rated TD severity and patient perceptions. The study assessed 1,148 patients and highlighted the need for clinicians to evaluate both the presence of TD and its effects on daily life for better treatment plans. This research underlines the necessity for comprehensive assessments of the quality of life in TD patients.
Neurocrine Biosciences (Nasdaq: NBIX) announced the presentation of data from three in vitro studies regarding the dissolution performance of INGREZZA® (valbenazine) capsule contents when mixed with soft foods or delivered via G-tube. Results indicated that crushing the capsules did not affect dissolution performance compared to whole capsules. This is significant for elderly patients with tardive dyskinesia, who may have difficulty swallowing. The data will be presented at the AMDA-PALTC23 Annual Conference from March 9-12 in Tampa, Florida, demonstrating the drug's versatility in administration methods.
Neurocrine Biosciences (NASDAQ: NBIX) will participate in two key investor conferences in Miami this March. The first event is the Barclays Global Healthcare Conference on March 15, 2023, where CEO Kevin Gorman and CFO Matt Abernethy will present at 10:45 a.m. Eastern Time. The second event is the Jefferies Biotech on the Bay Summit on March 16, 2023. Interested parties can access a live webcast of the Barclays presentation via their website, with a replay available for one month after the event.
On March 3, 2023, Neurocrine Biosciences (NASDAQ: NBIX) presented data at the AAGP 2023 Annual Meeting in New Orleans, focusing on the long-term treatment of tardive dyskinesia (TD) in older and elderly patients using INGREZZA (valbenazine). The findings showed that over 80% of patients aged 65+ achieved a clinically meaningful reduction in TD symptoms after 48 weeks of treatment. The study highlighted significant improvements in AIMS total scores and psychiatric stability across both age groups. The results are expected to inform treatment decisions for older adults at risk of TD.
On February 14, 2023, at 12:00 p.m. Eastern Time, Neurocrine Biosciences (NASDAQ: NBIX) will present at the virtual SVB Securities Global Biopharma Conference. The presentation will be led by CEO Kevin Gorman and CFO Matt Abernethy. Interested parties can access the live webcast on the company’s website under the Investors section. A replay will be available approximately one hour post-event and archived for one month. Neurocrine Biosciences focuses on developing treatments for under-addressed neurological, neuroendocrine, and neuropsychiatric disorders, with a diverse portfolio and 12 mid-to-late-stage clinical programs.
Neurocrine Biosciences reported fourth quarter net product sales of $399 million for INGREZZA, contributing to full-year sales of $1.44 billion. The company projects net product sales guidance for 2023 between $1.67 - $1.77 billion. Key developments include the completion of enrollment in registrational studies for crinecerfont, aimed at treating congenital adrenal hyperplasia, with top-line results expected in the second half of 2023. Financial highlights show a GAAP net income of $89 million for Q4 2022, a significant improvement over the $7 million loss in Q4 2021. Total cash and marketable securities stood at $1.29 billion as of December 31, 2022.
FAQ
What is the current stock price of Neurocrine Biosciences (NBIX)?
What is the market cap of Neurocrine Biosciences (NBIX)?
What does Neurocrine Biosciences Inc. specialize in?
What are some key products of Neurocrine Biosciences?
What recent advancements has Neurocrine Biosciences made?
Who announced their retirement from Neurocrine Biosciences in 2024?
What is the focus of Neurocrine Biosciences' muscarinic receptor portfolio?
Where is Neurocrine Biosciences headquartered?
How can I learn more about Neurocrine Biosciences?
What impact has INGREZZA had on Neurocrine Biosciences?
What are the CAHtalyst™ studies?
What was the focus of Neurocrine Biosciences' recent presentations at ENDO 2024?
